Elanco (ELAN): insider & executive buying
Elanco · Health Care · ref. ETF XLV · price $24.49
In short — 7 insiders bought Elanco over ~6 months (7 buys, total $1.7M, latest Aug 20, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Elanco's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$24.49+32.7% over range
Aug 28, 25low $17.35 · high $26.84Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
83% recommend buying · 6 analysts
Latest insider buys on Elanco
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Aug 20, 26 | Kurzius Lawrence Erik | Dir | 40,000 | $936k |
| Aug 18, 26 | O'Neill Shiv | GC, CORP SEC | 3,998 | $94k |
| Aug 12, 26 | Harrington Michael J | Dir | 5,000 | $109k |
| Aug 7, 26 | Vanhimbergen Robert M | EVP, CFO | 4,200 | $97k |
| Aug 7, 26 | Herendeen Paul | Dir | 10,000 | $237k |
| May 15, 26 | Modi Rajeev A. | SEE REMARKS | 4,911 | $100k |
| May 15, 26 | Simmons Jeffrey N | Pres, CEO, Dir | 4,971 | $100k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Elanco's executives bought shares recently?
7 Elanco insider(s) bought $1.7M over ~6 months (latest Aug 20, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for ELAN?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Elanco? The JPI assistant answers using our backtest data.